SCHEMBL4131697

SCHEMBL4131697

COc1c(OC(F)(F)F)cccc1C(=O)c1cc(Cl)ccc1NC(=O)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 3/20 0.44
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
GAA P10253 2/20 0.42
CCR9 P51686 2/20 0.42
P2RX1 P51575 1/20 0.41
KDM4E B2RXH2 5/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 2/20 0.41
ESR1 P03372 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13776154 0.92 MEN1 (0.45) CNR2MEN1KMT2ARAB9AMAPT
SCHEMBL5520431 0.91 MEN1 (0.49) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4116756 0.85 TMPRSS4 (0.47) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4124342 0.85 MAPT (0.52) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4123840 0.84 KMT2A (0.47) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4115436 0.82 MEN1 (0.49) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4118877 0.82 RECQL (0.49) KCNK3KCNK9P2RX1TMPRSS4
SCHEMBL4118434 0.80 RXFP1 (0.48) RAB9ASMN1; SMN2GAAKDM4EPOLB
SCHEMBL13776046 0.79 SMN1; SMN2 (0.52) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL4109319 0.79 SMN1; SMN2 (0.48) MEN1KMT2ARAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR CNR2 1807/4885MEN1 2041/4885KMT2A 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.